Sunday, June 19, 2016
Novartis aims to nearly triple biosimilar drugs on market by 2020
KUFSTEIN, Austria (Reuters) - Switzerland's Novartis pledged to nearly triple its number of biosimilar drugs on the market by 2020, raising its bet that cheaper versions of blockbuster cancer and immune system medicines will snatch billions in rivals' profits.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment